Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 11/20 | 0.56 |
| ▸ | PPARG | P37231 | 5/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | GLB1 | P16278 | 1/20 | 0.32 |
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18244654 | 0.90 | RXRA (0.70) | RXRAPPARGEGFR | |
| SCHEMBL30389769 | 0.90 | RXRA (0.70) | RXRAPPARGEGFR | |
| SCHEMBL12182065 | 0.90 | RXRA (0.70) | RXRAPPARGEGFR | |
| SCHEMBL18245005 | 0.89 | RXRA (0.67) | RXRAPPARGCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL30389738 | 0.89 | RXRA (0.67) | RXRAPPARGCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL18245004 | 0.89 | RXRA (0.67) | RXRAPPARGCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL24101806 | 0.83 | RXRA (0.61) | RXRAPPARGEGFRERBB2IGF1R | |
| SCHEMBL30486797 | 0.83 | RXRA (0.61) | RXRAPPARGEGFRERBB2IGF1R | |
| SCHEMBL8430717 | 0.80 | RXRA (0.39) | RXRAPPARGEGFR | |
| SCHEMBL25306462 | 0.76 | RXRA (0.51) | RXRAPPARGHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340324-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340324-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | RXRA, RXRG, RXRB | RXRA 1/4885PPARG 8/4885CSNK2A2 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.